Skip to main content
. 2014 Jul 15;46(3):288–296. doi: 10.4143/crt.2014.46.3.288

Table 1.

Patient characteristics according to their mean glucose levels

Quartile of mean glucose (% of patients)
p-value
Group 1 (n=52) Group 2 (n=51) Group 3 (n=51) Group 4 (n=52)
Age at diagnosis metastatic CRC (yr) 0.038
 Mean±SD 59.7±12.4 60.1±9.8 63.9±11.5 67.7±9.6
Gender 0.038
 Male 61.5 78.4 56.9 76.9
 Female 38.5 21.6 43.1 23.1
ECOG performance status 0.082
 0, 1 88.5 82.4 70.6 86.5
 ≥ 2 11.5 17.6 29.4 13.5
BMI (kg/m2) 0.701
 < 25 76.9 70.6 66.7 73.1
 ≥ 25 23.1 29.4 33.3 26.9
Comorbidity conditions by CCI scale 0.007
 0, 1 98.1 96.1 86.3 80.8
 ≥ 2 1.9 3.9 13.7 19.2
Diabetes mellitus < 0.001
 Yes 0 0 17.6 69.2
 No 100 100 82.4 30.8
Hypertension 0.076
 Yes 19.2 29.4 35.3 42.3
 No 80.8 70.6 64.7 57.7
Location of primary tumor 0.382
 Colon 50.0 45.1 58.8 59.6
 Rectum 50.0 54.9 41.2 40.4
Stage 0.072
 M1a 19.2 43.1 29.4 32.7
 M1b 80.8 56.9 70.6 67.3
No. of palliative chemotherapies 0.598
 1 59.6 52.9 58.8 63.5
 2 21.2 33.3 29.4 28.8
 ≥ 3 19.2 13.7 11.8 7.7
Use of dexamethasone (mean±SD)
 Dose (mg) 278.4±317.1 224.9±263.7 246.9±284.7 249.5±234.4 0.808
 Duration (days) 22.0±21.8 23.1±25.8 25.1±28.6 28.9±43.5 0.689
Use of megestrol acetate (mean±SD)
 Dose (g) 0.43±1.17 0.40±0.94 0.66±1.16 0.71±1.58 0.468
 Duration (days) 17.0±28.5 25.4±49.9 33.0±54.8 39.0±78.1 0.213

CRC, colorectal cancer; SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CCI, Charlson Comorbidity Index; M1a, metastasis confined to one organ or site (e.g., liver, lung, ovary, or non-regional node); M1b, metastases in more than one organ/site or the peritoneum.